Matthew Frank, MD, PhD


Matthew Frank, MD, PhD, on Tackling Antigen Loss and Absence in Hematological Malignancies

The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed potential methods for optimizing CAR-T efficacy that could be explored in the future.

Mansi R. Shah, MD


Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma: Mansi R. Shah, MD

The hematologist/oncologist from Rutgers Cancer Institute of New Jersey discussed ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel.

Kelly Garvin, BSN, RN


CAR T Therapy in Non-Hodgkin Lymphoma: Kelly Garvin, BSN, RN

The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.

James Lim, PhD


James Lim, PhD, on Addressing Lingering Needs in Research Process Development and Clinical Manufacturing

The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s efforts to introduce new technologies for improving cell therapy development and manufacturing.

Arshad Khanani, MD


Arshad Khanani, MD, on Comparing Wet AMD Gene Therapy 4D-150 to Aflibercept in a Randomized Clinical Trial

The assistant professor in the department of pediatrics at the University of Florida College of Medicine discussed also discussed the latest results announced from the phase 2 portion of the PRISM study.

Javier L. Munoz, MD, MS, FACP


CAR T and Other Options for Relapsed/Refractory Follicular Lymphoma: Javier L. Munoz, MD, MS, FACP

The director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.

Paul Stewart, PhD


Paul Stewart, PhD, on the Potential of Genetic Medicine Approaches in Squamous Cell Lung Cancer

The assistant member at the Department of Biostatistics and Bioinformatics at Moffitt Cancer Center shared the potential implications of the findings he is presenting at the 2023 AACR annual meeting on proteomics and metabolomics.

Yazeed Sawalha, MD


ASCT Utilization Rates in Mantle Cell Lymphoma: Yazeed Sawalha, MD

The hematologist at Ohio State University Comprehensive Cancer Center–The James discussed utilization rates of autologous stem cell transplant in patients with mantle cell lymphoma.

Juan Francisco Cabello, MD


Juan Francisco Cabello, MD, on How Gene Therapy Fits Into the Global Initiative for Newborn Screening

The head of the Pediatric Neurology Fellowship Program at the University of Valparaiso in Chile discussed how a lack of cost-effectiveness may hold back the potential of newborn screening in gene therapy.

Gerhard Ehninger, MD


Gerhard Ehninger, MD, on Managing Toxicities With Switchable CARs in AML

The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.

Matt Angel, PhD


Matt Angel, PhD, on Addressing Unmet Needs in Acute Myeloid Leukemia and Solid Tumors

The chief executive officer and president of Eterna Therapeutics discussed the company’s new collaboration with the University of Texas MD Anderson Cancer Center.

Michael Singer, MD, PhD


Combining RNA and CAR T-Cell Therapy for Myasthenia Gravis

Michael Singer, MD, PhD, cofounder and chief scientific officer of Cartesian Therapeutics, discussed the company’s lead candidate, Descartes-08.

Travis Drow, BS


Travis Drow, BS, on Evaluating Engineered Tregs for Potential in Treating Multiple Sclerosis

The research scientist at Seattle Children's Research Institute discussed mouse model research he presented at ASGCT’s 2024 Meeting.

Matthew Lunning, DO, FACP


Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.

Adham Bear, MD


Adham Bear, MD, On Immunotherapy Targeting Mutant KRAS

The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.

Harikrishna Nakshastri, PhD


Harikrishna Nakshastri, PhD, on Characterizing Early Oncogenesis in Breast Cancer

The professor of breast cancer research at Indiana University discussed new research with the TONSL gene from Indiana University.

Erika Fullwood Augustine, MD, MS


Erika Fullwood Augustine, MD, MS, on Optimizing End Points for Rare Disease Clinical Trials

The associate chief science officer of the Kennedy Krieger Institute discussed an aspect of clinical trial design highly relevant to gene therapy development for rare diseases.

Susan Foy, PhD


Susan Foy, PhD, on Evaluating Personalized, Neoantigen-Specific T Cell Therapy in Solid Tumors

The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.

Susie Long, PharmD


Susie Long, PharmD, on ASTCT’s 2023 Fundamentals of HCT Training Course

The pediatric clinical pharmacist in stem cell transplant and cellular therapy at the University of Minnesota Masonic Children’s Hospital and M Health Fairview offered an in-depth preview of the upcoming virtual meeting.

Robert M Califf, MD, MACC


Robert M Califf, MD, MACC, on 2023’s Landmark FDA Approvals of Cell and Gene Therapies

The commissioner of food and drugs at the FDA discussed the year's approvals and what may be coming on the horizon in the realm of advanced therapeutics.

Brian Culley


Brian Culley, MS, on Sharing Knowledge From the Development of Spinal Cord Injury Cell Therapy

The chief executive officer of Lineage Cell Therapeutics discussed findings related to its cell therapy OPC1 that the company presented at the first Annual SCI Investor Symposium.

Jakub Svoboda, MD


Jakub Svoboda, MD, On Improving CR Rates With Next-generation CAR T Therapies

The associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.

Joshua Richter, MD


Looking Forward in Relapsed/Refractory Multiple Myeloma Treatments

James Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.

Thomas McCauley, PhD


Thomas McCauley, PhD, on Proof-of Concept With In Vivo Epigenomic Editing

The chief scientific officer at Omega Therapeutics discussed how the MYCHELANGEO-1 trial may validate the company’s OEC platform.

Karen Pignet-Aiach


Developing Gene Therapies for Indications With Unmet Needs

The chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.

Robert J. Hopkin, MD


Robert J. Hopkin, MD, on Safely Delivering Gene Therapy for Fabry Disease

The associate professor of clinical pediatrics at Cincinnati Children's discussed the latest data from the phase 1/2 STAAR study of isaralgagene civaparvovec.

Amod Sarnaik, MD


Overcoming Barriers to TIL Use in Patients With Solid Tumors

Closing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.

Michael Leek, PhD


Michael Leek, PhD, on Manufacturing Challenges in Cell Therapy

The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.

Mathula Thangarajh, MD, PhD


Mathula Thangarajh, MD, PhD, on the Potential of Gene Therapy to Address Cognitive Symptoms in Muscular Dystrophy

The child neurologist and neuromuscular physician at Virginia Commonwealth University also discussed the session she chaired at the 2023 MDA Clinical and Scientific Conference.

Christopher Slapak, MD


Future Research With Stem Cell Therapies in Hematologic Malignancies

The chief executive and chief medical officers of Vor Biopharma discussed the company’s future research and plans.

© 2024 MJH Life Sciences

All rights reserved.